Janssen Pharmaceutical Companies of Johnson & Johnson officially opened a new vaccines launch facility in Leiden, the Netherlands. The new facility represents a significant investment by the company in novel vaccines development, global health and security, and pandemic preparedness efforts. In addition, the facility features innovative technological and manufacturing platforms to support the large-scale production of vaccines for clinical trials and global launch.
The company will utilize a number of research and development (R&D) platforms at the vaccines launch facility, including Janssen’s proprietary AdVac viral vector vaccines technology and the company’s PER.C6 manufacturing platform.
“This new center represents a significant commitment by Johnson & Johnson in our mission to change the trajectory of human health,” said Johan Van Hoof, M.D., global therapeutic Aaea head IDV, vaccines, Janssen Pharmaceuticals R&D and managing director, Janssen Vaccines & Prevention B.V. “By investing locally, we hope to protect globally by ensuring that innovative and effective vaccines become available to the people that need them wherever they may live.”
(Source: Invest in Holland)
